Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Apogee Therapeutics, Inc.NASDAQ: APGE
Property, Plant & Equipment (Net) · Q2 FY2026 · quarter ended Jun 2026
Property, plant & equipment (net) falls 32.3% from a year ago
Property, plant & equipment (net) stood at $11.53M at the end of Q2 FY2026, down 32.3% from a year earlier and down 11.2% from the prior quarter.
Context
- Property, plant & equipment (net) amounted to 0.9% of total assets at the end of Q2 FY2026, down 1.7 pp from a year earlier.
- Property, plant & equipment (net) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -32.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 14.38M USD
- Year-over-year change
- +7.9%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.38M | +7.9% |
| FY2024 | 2024-12-31 | 13.32M | +413.6% |
| FY2023 | 2023-12-31 | 2.59M | — |
| FY2022 | 2022-12-31 | 0 | — |
Property, Plant & Equipment (Net) vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -32.3% is the 9th highest of 10, against a peer median of -8.2%.
- Property, plant & equipment (net) amounts to 0.9% of total assets for APGE, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥829.59M CNY | -8.4% | +8.5% | 20.9% |
| Sep 2026 | $439.5M USD | +73.2% | +35.5% | 26.1% | |
| Mar 2026 | $239M USD | -8.4% | +0.9% | 18.4% | |
| Jun 2026 | $62.59M USD | -6.5% | -5.5% | 5.8% | |
| Sep 2026 | $21.19M USD | +8.5% | +238.2% | 2.0% | |
| Sep 2026 | $12.52M USD | -21.0% | -3.2% | 1.0% | |
| Jun 2026 | $11.53M USD | -32.3% | — | 0.9% | |
| Mar 2026 | $10.52M USD | -8.2% | +110.2% | 1.6% | |
| Jun 2026 | $1.72M USD | +252.0% | +2.8% | 0.2% | |
IRONDisc Medicine, Inc. | Sep 2026 | $1.59M USD | -35.2% | +12.2% | 0.2% |
| Peer median (excluding APGE) | — | -8.2% | +8.5% | 2.0% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.